Nextgen Healthcare Inc (NASDAQ:NXGN) Director Sheldon Razin sold 1,113 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $19.03, for a total value of $21,180.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Sheldon Razin also recently made the following trade(s):
- On Thursday, June 13th, Sheldon Razin sold 4,018 shares of Nextgen Healthcare stock. The shares were sold at an average price of $19.06, for a total value of $76,583.08.
NASDAQ:NXGN traded up $0.49 during trading hours on Monday, reaching $20.39. The company had a trading volume of 227,200 shares, compared to its average volume of 264,618. The business has a 50-day simple moving average of $19.13. Nextgen Healthcare Inc has a one year low of $13.89 and a one year high of $23.73. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of 33.43, a PEG ratio of 3.44 and a beta of 1.03. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 0.03.
A number of institutional investors have recently bought and sold shares of NXGN. Parallel Advisors LLC acquired a new position in shares of Nextgen Healthcare during the first quarter valued at $26,000. PNC Financial Services Group Inc. increased its holdings in shares of Nextgen Healthcare by 37.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,387 shares of the company’s stock worth $36,000 after acquiring an additional 649 shares in the last quarter. Quantamental Technologies LLC bought a new stake in shares of Nextgen Healthcare in the fourth quarter worth about $60,000. MERIAN GLOBAL INVESTORS UK Ltd bought a new stake in shares of Nextgen Healthcare in the first quarter worth about $109,000. Finally, Convergence Investment Partners LLC bought a new stake in shares of Nextgen Healthcare in the first quarter worth about $152,000. 69.96% of the stock is currently owned by institutional investors.
A number of analysts have issued reports on the company. TheStreet raised Nextgen Healthcare from a “c+” rating to a “b” rating in a report on Tuesday, May 28th. Dougherty & Co lowered Nextgen Healthcare from a “buy” rating to a “neutral” rating in a report on Wednesday, May 29th. Zacks Investment Research raised Nextgen Healthcare from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Friday, April 26th. Svb Leerink raised Nextgen Healthcare from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $19.00 to $22.00 in a report on Thursday, April 25th. Finally, Leerink Swann raised Nextgen Healthcare from a “market perform” rating to an “outperform” rating in a report on Thursday, April 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Nextgen Healthcare presently has a consensus rating of “Hold” and a consensus target price of $19.50.
About Nextgen Healthcare
NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.
Further Reading: Why are analyst ratings important in trading stocks?
Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.